Cargando…
ATM inhibition synergizes with fenofibrate in high grade serous ovarian cancer cells
While therapies targeting deficiencies in the homologous recombination (HR) pathway are emerging as the standard treatment for high grade serous ovarian cancer (HGSOC) patients, this strategy is limited to the ~50% of patients with a deficiency in this pathway. Therefore, patients with HR-proficient...
Autores principales: | Chen, Chi-Wei, Buj, Raquel, Dahl, Erika S., Leon, Kelly E., Aird, Katherine M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527645/ https://www.ncbi.nlm.nih.gov/pubmed/33024871 http://dx.doi.org/10.1016/j.heliyon.2020.e05097 |
Ejemplares similares
-
ATM inhibition drives metabolic adaptation via induction of macropinocytosis
por: Huang, Zhentai, et al.
Publicado: (2022) -
ATM in senescence
por: Aird, Katherine M., et al.
Publicado: (2015) -
Cell Origins of High-Grade Serous Ovarian Cancer
por: Kim, Jaeyeon, et al.
Publicado: (2018) -
Suppression of p16 alleviates the senescence-associated secretory phenotype
por: Buj, Raquel, et al.
Publicado: (2021) -
Loss of p16: A Bouncer of the Immunological Surveillance?
por: Leon, Kelly E., et al.
Publicado: (2021)